TNFRSF17 and plasma cell myeloma: Currently approved CAR T-cell products target CD19 and B-cell maturation antigen (BCMA), allowing successful treatment and unprecedented responses in r/r diffuse large B-cell lymphoma (DLBCL), r/r B-cell acute lymphoblastic leukemia (B-ALL), r/r mantle cell lymphoma (MCL) and, more recently, r/r multiple myeloma [1,2].